Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that effectively controls blood glucose and promotes weight loss, but discontinuation often leads to weight regain and glycemic deterioration
When combined with propranolol, these GLP-1 side effects may be compounded by propranolol's own ability to slow gastrointestinal motility, leaving some patients with more pronounced digestive symptoms
Why switch from semaglutide to tirzepatide Here are a few reasons you should switch from semaglutide to tirzepatide: More significant weight loss with tirzepatide Clinical trial data show that tirzepatide is more effective for chronic weight management than semaglutide
Acute pancreatitis typically arises as the pancreas tries to heal from a short-term, minor injury, often resolving itself within a few days through hydration, rest, and pain management
Potential Research Applications: Testosterone stimulation and LH activity studies Fertility and reproductive hormone models Testicular function and spermatogenesis research Endocrine system modulation investigations For laboratory research use only